Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan ‐O‐ AP and LixiLan ‐L‐ CN
Authors' conclusion
iGlarLixi improves dTITR, GV, and PPG control versus iGlar or Lixi in Asian Pacific individuals with T2D.
Study context
- Population
- Asian Pacific individuals with suboptimally controlled T2D on oral antidiabetic drugs (LixiLan-O-AP) or basal insulin (LixiLan-L-CN)
- Comparison
- iGlarLixi vs iGlar or lixisenatide (Lixi)
Methodological detailstwo phase 3 trials
- Two phase 3 trials
Primary result
As reported in the abstract
Change in derived time in tight range (dTITR) (3.9-7.8 mmol/L), from SMBG profiles · baseline to EOT (Week 24 or 30, respectively)
Least squares mean difference
15.03 %
iGlarLixi vs iGlar · LixiLan-O-AP
Least squares mean difference
29.14 %
iGlarLixi vs Lixi · LixiLan-O-AP
Least squares mean difference
15.93 %
iGlarLixi vs iGlar · LixiLan-L-CN
Further findings
> 50% dTITR rate, LixiLan-O-AP · EOT
| Outcome | iGlarLixi | iGlar | Lixi |
|---|---|---|---|
| > 50% dTITR rate, LixiLan-L-CN · EOT | 53.6% | 26.4% | — not stated in the abstract |
— not stated in the abstract
Glycaemic variability (GV) (SD of self-monitoring of blood glucose (SMBG), high blood glucose index (HBGI), mean absolute glucose (MAG), mean amplitude of glycaemic excursions (MAGE)) and PPG (0.5, 1, 2 h) · end-of-treatment (EOT)
- iGlarLixi provided generally greater reductions in SD of SMBG, HBGI, MAG, MAGE and 0.5-, 1- and 2-h PPG vs iGlar or Lixi and greater 2-h PPG < 10.0 mmol/L achievement rates at EOT
Original publication
Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan ‐O‐ AP and LixiLan ‐L‐ CN. Diabetes Obes Metab. Published 1 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →